OBJECTIVE Sex differences are found in most components of the insulin resistance syndrome and the associated cardiovascular risk profile. These differences are attributed to sex-specific sex steroid profiles, but the effects of sex steroids on the individual components of the insulin resistance syndrome remain incompletely understood. RESULTS Oestrogens + antiandrogens increased highdensity lipoprotein (HDL)-cholesterol and decreased LDL-cholesterol, and HL activity, which are considered beneficial. But this combination also increased triglycerides, blood pressure, subcutaneous fat and visceral fat, and decreased the LDL-particle size, LPL activity and insulin sensitivity, which are all considered detrimental. Testosterone reduced HDLcholesterol and the LDL-particle size, and increased triglycerides and HL activity. An android fat distribution was induced (i.e. decreased subcutaneous and increased visceral fat). Blood pressure, total and LDLcholesterol, LPL activity and insulin sensitivity were mainly unaffected.
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CONCLUSIONS The effects of cross-sex hormone treatment -in the dosages used in this study -in healthy, nonobese, young transsexual subjects do not show unequivocally that female sex steroids, given in large amounts to male subjects, have beneficial effects on cardiovascular profile and that high dose testosterone administration to female subjects is detrimental with respect to cardiovascular risk.
Men have a two-to fivefold increased risk of death from cardiovascular disease compared to women during middle age (Tunstall-Pedoe et al ., 1994; Jousilahti et al ., 1999) . Differences in sex steroids are believed to be, at least in part, responsible for this lower risk in women. Women seem to be protected by endogenous oestrogens, and indeed, oestrogens have been shown to exert several beneficial effects on lipid profiles and other cardiovascular risks factors (Godsland et al ., 1987; Skafar et al ., 1997) . Androgens are often considered to be detrimental, particularly because of their proatherogenic effects on lipid metabolism (Wild, 1995) . However, oestrogen / progestagen administration did not reduce cardiovascular mortality (and morbidity) in randomized intervention trials; neither in women with (Hulley et al ., 1998; Herrington et al ., 2000) or without heart disease in the recent Women's Health Initiative mega-trial (Writing Group for the Women's Health Initiative Investigators, 2002) , nor did oestrogen administration in men with heart disease (The Coronary Drug Project, 1973) ; while observations in men suggest that low rather than high androgen levels are related to cardiovascular disease (CVD; Barrett-Connor, 1995; Alexandersen et al ., 1996) .
Several risk factors for atherosclerotic vascular disease are clustered in the 'insulin resistance syndrome', characterized by hyperinsulinaemia, insulin resistance, atherogenic lipoprotein phenotype [i.e. high fasting triglycerides, low high-density lipoproteins (HDL)-cholesterol, small and dense low-density lipoproteins (LDL)], hypertension and a visceral localization of body fat (DeFronzo & Ferrannini, 1991; Laws & Reaven, 1993) . Sex differences have been described in lipid, glucose, insulin (sensitivity) and blood pressure (Freedman et al ., 1990; Seidell et al ., 1991; Larsson et al ., 1992; Lemieux et al ., 1994) , and differences in sex steroids may play a role in these sex differences. However, some of these differences (e.g. fasting triglycerides) may be secondary to sex differences in visceral fat depots (Freedman et al ., 1990; Seidell et al ., 1991; Larsson et al ., 1992; Lemieux et al ., 1994) . Central adiposity (i.e. excess fat in the abdominal subcutaneous and visceral fat depots), which is typical in men, is associated with the insulin resistance syndrome in both sexes. Premenopausal women store fat mainly in the subcutaneous depots on hips and thighs, which shift towards a more visceral localization after menopause. Oestrogen + antiandrogen administration have been shown to increase the subcutaneous fat area (Elbers et al ., 1999) , whereas testosterone administration increases muscle size and decreases fat mass, mostly due to a decrease in the subcutaneous fat area (Elbers et al ., 1999; Singh et al ., 2002) .
The atherogenic lipoprotein phenotype is more prevalent in men than in premenopausal women. Differences in sex steroid milieu may explain part of the sex difference in HDL-cholesterol levels, as oestrogens raise (Schaefer et al ., 1983; Bagatell et al ., 1994; Crook & Godsland, 1998) and androgens lower HDLcholesterol von Eckardstein et al ., 1997; Singh et al ., 2002) . Although LDL-cholesterol levels show no consistent sex difference, men generally have higher concentrations of small, dense LDL particles than women (Krauss, 1994; Nikkila et al ., 1996) . Sex steroids may regulate levels and composition of lipoproteins through lipolytic enzyme activity, lipoprotein lipase (LPL) and hepatic lipase (HL). HL decreases HDL-cholesterol, catalyses the conversion of lipid-enriched HDL 2 particles to lipid-poor HDL 3 particles, and increases the formation of small, dense LDL particles. HL activity is increased by treatment with androgens Taggart et al ., 1982; Sorva et al ., 1988) and decreased by oestrogens (Tikkanen et al ., 1982; Applebaum-Bowden et al ., 1989; Brinton, 1996) .
Another possible mechanism for the sex difference in cardiovascular risk profile may involve insulin sensitivity and blood pressure. Administration of high-dose oestrogens (Godsland et al ., 1992; Polderman et al ., 1994; Perseghin et al ., 2001 ) may induce some insulin resistance, but physiological doses may not have such adverse effects (Brussaard et al ., 1997) . Effects of androgens on insulin resistance and glucose intolerance are conflicting (Cohen & Hickman, 1987; Friedl et al ., 1989; Marin et al ., 1992; Singh et al ., 2002) .
In summary, many of the cardiovascular risk factors clustered in the insulin resistance syndrome are known to be affected by sex steroids. The aim of the present intervention study is to assess longitudinally the temporal relationship between the effects of oestrogen and of testosterone administration on the lipid profile, insulin sensitivity and body fat distribution in nonobese, relatively young transsexual subjects. No previous study has included all these elements of the insulin resistance syndrome.
Subjects and methods

Subjects
In this study, 20 male-to-female (M-F ) and 17 female-to-male (F-M) transsexuals participated. M-F transsexuals had a mean age ( ± SD) of 26 ± 6 years (range 18-36) and a mean body mass index (BMI) of 20·6 ± 2·6 kg /m 2 (range 16·1-24·5), and were studied before and during 12 months of treatment with 100 µ g/ day ethinyl oestradiol (EE; Lynoral, Organon, Oss, the Netherlands) and 100 mg /day cyproterone acetate (CA; a progestational antiandrogen; Androcur, Schering, Berlin, Germany) daily. F-M transsexuals had a mean age of 23 ± 5 year (range 16 -34) and a mean BMI of 21·7 ± 3·5 kg /m 2 (range 16·6 -29·0), and were studied before and during 12 months of treatment with one intramuscular (i.m.) injection of 250 mg testosterone esters every 2weeks (Sustanon 250, Organon). All subjects were eugonadal and healthy as assessed by medical history, physical examination and biochemical criteria; there was no evidence of renal or cardiovascular disease, diabetes mellitus, or use of sex hormones prior to inclusion. F-M transsexuals had normal regular menstrual cycles. All subjects gave their informed consent, and the study was approved by the ethics review board of the VU University Medical Center in Amsterdam.
Sex steroids and SHBG
In all subjects, venous blood samples were taken in the morning between 09·00 and 10·30 h after an overnight fast at baseline, and again after 2 and 12 months of cross-sex hormone administration. Baseline blood samples in F-M transsexuals were taken between days 5 and 9 of the menstrual cycle, presumably in the follicular phase. Following hormone treatment, menstrual activity ceased and blood was drawn during treatment within 5-9 days after the preceding testosterone injection. Standardized radioimmunoassays were used to measure serum levels of 17 β -oestradiol and testosterone. Serum levels of sex hormone-binding globulin (SHBG) and insulin were measured by immunoradiometric assays.
Lipid profile and lipolytic enzyme activity
Standard laboratory test kits were used to determine HDLcholesterol (enzymatic colourimetric method after phosphotungstic acid/magnesium chloride precipitation; Boehringer Mannheim, Mannheim, Germany), triglycerides (enzymatic hydrolysis of triglycerides with subsequent determination of liberated glycerol by colourimetry; Boehringer Mannheim), and free fatty acids (FFA; enzymatic colourimetric method; Wako Chemicals GmbH, Neuss, Germany). Separation of lipoproteins was performed in a Beckman Optima-TLX ultracentrifuge with a fixed-angle TLA 120·2 rotor. Prior to ultracentrifugation, plasma samples (0·5 ml) were mixed with 0·5 ml of sodium chloride solution of density 1·006 kg / l. After ultracentrifugation at 510 000 g for 1 h 40 min at 15 ° C, the supernatant, containing very lowdensity lipoproteins (VLDL), was separated from the infranatant, containing LDL and HDL, by tube slicing. For determination of total HDL and HDL 3 in the infranatant fraction, we used a dual precipitation method with dextran sulphate-Mg 2+ reagent. Total cholesterol was measured in the various fractions obtained by ultracentrifugation and precipitation on a Cobas Bio-analyser using an enzymatic, colourimetric test kit from Boehringer Mannheim. LDL cholesterol was calculated as the difference between cholesterol in the infranate and total HDL cholesterol. HDL 2 -cholesterol was calculated as the difference between total HDL cholesterol and HDL 3 -cholesterol. LDL was isolated by dual spin ultracentrifugation between 1·019 and 1·063 kg/l. LDL size was determined by highperformance gel-filtration chromatography as recently described (Scheffer et al ., 1997) . In the LDL fraction, total cholesterol, free cholesterol, phospholipids and triglycerides were analysed by enzymatic, colourimetric testkits (Boehringer Mannheim). Esterified cholesterol was calculated as the difference between total and free cholesterol. Protein was determined by a modified Lowry procedure (Markwell et al ., 1981) . Lipid constituents were expressed as mmol / g LDL protein.
For determination of LPL activity and HL activity, intravenous heparin (100 IU/kg body weight) was administered in order to liberate the lipase enzymes from the endothelium. Fifteen minutes after administration, a blood sample was collected in heparin-containing tubes, and immediately put on ice. The sample was centrifuged for 15 min at 2000 g , and the plasma was stored at − 70 ° C until determination. LPL and HL were determined by a radioenzymatic method . In the assay, a suspension of tri[
C]oleoylglycerol stabilized with arabic gum was used as substrate. LPL activity was measured after inhibition of HL activity by a specific antiserum. Pooled normal human serum was added as source of apo C 2 . HL activity was measured in a medium containing 1·0 m NaCl to inhibit LPL activity but without additional serum. Assays were performed at 28 ° C. Lipase activities are expressed as µ mol fatty acid released in 1 h /ml of postheparin plasma.
Blood pressure, insulin sensitivity and anthropometry
Diastolic and systolic blood pressures were measured every 5 min for 2 h using an automatic device (BP-8800, Colin Hayaski, Japan), with subjects in sitting position (on a bed). The average of all measurements was calculated. Fasting levels of glucose were measured by a hexokinase method (Boehringer Mannheim).
In 18 M-F and 16 F-M transsexuals, insulin sensitivity was assessed at baseline and after 12 months treatment by a two-step hyperinsulinaemic euglycaemic clamp technique (Polderman et al ., 1994) . In short, the two-step clamp procedure consisted of two consecutive 2-h periods, with an insulin infusion rate of 62·5 mU/kg FFM/ h during the first step and 187·5 mU/ kg FFM/h during the second step. The insulin solution for intravenous infusion was prepared by adding 0·5 ml human insulin (100 IU/ ml; Velosulin ® , Novo Nordisk A/ S, Bagsvaerd, Denmark) and 4·5 ml human albumin 20% (Central Blood Transfusion Laboratory, Amsterdam, the Netherlands) to 45 ml isotonic sodium chloride 0·9%, to a final insulin concentration of 1 IU/ml. The clamp procedure was started 30 min after cannulation (0 min). After the start of the insulin infusion, blood glucose levels were measured every 5 min with the use of a Yellow Springs Instruments Glucose Analyser (glucose oxidase method; Yellow Springs, OH, USA) and glucose 20% infusion rate was adjusted to maintain blood glucose concentration at the fasting level (i.e. mean blood glucose level from − 30 to 0 min). Blood samples for the determination of insulin levels were collected at − 30, 0 and every 30 min until the end of the insulin infusion (240 min), and were stored at − 20 ° C until determination. Insulin levels were assessed by an immunoradiometric-assay (Biosource Diagnostics, Fleurus, Belgium). We previously observed that endogenous glucose production was completely suppressed at the insulin levels reached during both steps, and that endogenous glucose production was not affected by the cross-sex hormone treatment (Polderman et al ., 1994) . Whole-body glucose uptake was calculated from the steady-state glucose infusion rate in the second hour of each step (mg / min), and also expressed per kg FFM, i.e. M -value (mg / kg FFM /min). In order to compare the results obtained at baseline with those after 12 months cross-sex hormone treatment, glucose utilization was corrected for insulin levels during the last 60 min of both steps of the clamp procedure.
Height was measured to the nearest 0·1 cm, and weight was recorded to the nearest 0·1 kg with subjects wearing only underwear. Before and after 12 months of treatment, magnetic resonance imaging was used to quantify areas on the same imager using the same parameters (as described in more detail in Elbers et al ., 1997) . In short, transverse images were obtained at the level of the abdomen (lower edge of the umbilicus, three images), the hip (upper margin of the great trochanters, two images), and the thigh ( just below the gluteal fold, two images). The imageanalysing computer program (developed by our Department of Biomedical Engineering) is based on a seed-growing procedure. The areas of the circumscribed abdominal subcutaneous and visceral fat depots were calculated by converting the number of pixels to cm 2 and the average of the two or three areas was taken.
The sum of the subcutaneous fat areas at the level of the hip and thigh was calculated (gluteofemoral fat). To reduce variability, all measurements were taken by one experienced observer. The intraobserver coefficients of variation were 2·3% for subcutaneous fat and 9·8% for visceral fat (Elbers et al ., 1997) .
Statistical analyses
Variables with right skewed distributions were logarithmically transformed before analysis to normalize their distributions.
To compare baseline differences between males and females, a Student's t -test was used. In both groups of M-F and F-M transsexuals separately, a paired sample t-test or an analysis of variance ( anova ) for repeated measurements was used to analyse the effects in time of cross-sex hormone administration. Analysis of covariance was performed to evaluate the effect of varying steady-state insulin levels during the two-clamp procedure (before and after treatment) with M -value as dependent variable and insulin level as covariate. The Pearson's correlation coefficient was used to correlate baseline values and to correlate values after 12 months treatment. If values were below the lower limit of detection, the value of that lower limit was used for statistical analysis (for testosterone 1·0 nmol/l, for LH 0·3 IU/l and for FSH 0·5 IU/ l). A two-tailed P < 0·05 was considered statistically significant and statistical analyses were not corrected for multiplicity. The software used was SPSS for Windows 8·0 (SPSS Inc., Chicago, IL, USA).
Results
Levels of sex steroids and SHBG
In M-F transsexuals, administration of EE + CA suppressed serum testosterone to undetectable levels in all subjects; ethinyl oestradiol cannot be detected by the 17 β -oestradiol assay used, but the oestrogenic effect was reflected by increased SHBG levels and clinical signs (Table 1 ). In F-M transsexuals, parenteral testosterone increased serum testosterone to supraphysiological levels, and decreased serum SHBG. Levels of 17 β -oestradiol were only slightly suppressed after 2 months and remained at this level after 12 months treatment ( P = 0·14; Table 2 ).
Lipid profile and lipolytic enzyme activity
At baseline, HDL 2 -cholesterol levels were lower in males vs. females ( P = 0·02). Baseline values of other lipoproteins, LDL size and LDL composition were similar between the sexes, although HDL-cholesterol levels were slightly lower in males vs. females ( P = 0·07). No baseline sex differences were observed in HL activity, while males had a somewhat lower LPL activity than females ( P = 0·06). Only in M-F transsexuals, baseline levels of HDL-cholesterol and its subfractions showed significant negative correlations with HL activity ( − 0·55 ≤ r ≤ −0·48, P < 0·05), and significant positive correlations with LPL activity (0·48 ≤ r ≤ 0·55, P < 0·05). In M-F transsexuals, EE + CA significantly increased HDL-cholesterol (by mean +24%), which was more pronounced for HDL 2 -cholesterol (by +84%) than HDL 3 -cholesterol (by +11%). HL activity was sharply reduced (by −64%), already after 2 months and remained at this low level after 12 months (Fig. 1) , whereas the decrease in LPL activity was less pronounced (by −23%). LDL-cholesterol significantly decreased (by −12%). These presumably beneficial effects were countered by the strong rise in fasting triglyceride levels (by +86%), and the size of the LDL particles becoming slightly though strongly significantly smaller (by −1·1%) as compared to baseline (Fig. 1) . These dense LDL particles became 'cholesterol-depleted' and high in triglyceride content (Table 1) . No statistically significant changes were observed in total cholesterol, VLDL-cholesterol and FFA.
In F-M transsexuals, testosterone significantly decreased levels of HDL-cholesterol (−20%) and its subfractions HDL 2 -and HDL 3 -cholesterol (by −40% and −15%, respectively), and increased HL activity (by +63%, Fig. 1 ), oppositely to the effects found upon EE + CA administration. Also compatible with a atherogenic lipoprotein phenotype were the increase in fasting triglycerides (by +33%) and the slight, though statistically significant, decrease in LDL size (by −0·4%). Similar to the results of EE + CA administration, upon testosterone administration no statistically significant changes were observed in total cholesterol, VLDL-cholesterol and FFA.
Neither in M-F nor in F-M transsexuals were significant correlations observed between the HL and LPL activities and LDL size and composition (data not shown).
Blood pressure, insulin sensitivity and anthropometry
In M-F transsexuals, administration of EE + CA increased both systolic and diastolic blood pressures, whereas in F-M transsexuals, administration of testosterone induced no changes in systolic or diastolic blood pressure (Tables 1 and 2) .
At baseline, the mean values of fasting glucose, fasting insulin, glucose utilization and M-value were not different in males vs. females. In M-F transsexuals, administration of EE + CA increased fasting insulin (by +50%). During both steps of the clamp procedure, glucose utilization and M-value significantly decreased (by approximately −33% during step 1 and −18% during step 2, Table 1 ). Fasting glucose did not change significantly.
In F-M transsexuals, testosterone changed neither fasting glucose nor fasting insulin nor glucose utilization. However, the M-value during the second step (i.e. exposure to supraphysiological insulin levels corrected for FFM) significantly decreased (Table 2) . Similar results were obtained after correction for circulating insulin levels during the last 60 min of both steps, both in M-F and in F-M transsexuals (data not shown). Insulin levels during the last 60 min of both steps of the clamp procedure were not associated with the M-value, in neither M-F nor F-M transsexuals (data not shown) At baseline, subcutaneous fat areas (i.e. sum of hip and thigh measurements) were smaller in males vs. females (P < 0·001). Visceral fat areas were not significantly different in males vs. females.
In M-F transsexuals, administration of EE + CA increased body weight (by +3·8 kg). The increase in the subcutaneous fat area (by +38%) was stronger than in the visceral fat area (by +18%, Table 1 ), reducing the ratio between visceral and subcutaneous abdominal fat by −29%. In F-M transsexuals, administration of testosterone also increased body weight (by +2·7 kg), but the subcutaneous fat area decreased (by −22%), and the visceral fat area increased (by +13%, Table 2 ), increasing the ratio between visceral and subcutaneous abdominal fat by +49%. Values are means ± SD, except for levels of fasting triglycerides: geometric mean (95% CI of the mean). *Ethinyl estradiol, which suppresses endogenous 17β-oestradiol, cannot be detected in conventional 17β-oestradiol assays. BMI, body mass index; FA, fatty acids; FFA, free fatty acids, FFM, fat free mass; gluc, glucose; HDL, high-density lipoprotein; HL, hepatic lipase, LDL, low-density lipoprotein; LPL, lipoprotein lipase; MRI, magnetic resonance imaging; ns, not statistically significant; SHBG, sex hormone-binding globulin; VLDL, very-low-density lipoprotein.
No consistent associations were found between fat areas and insulin sensitivity, neither at baseline nor after 12 months. Similarly, no consistent associations were observed between proportional changes, at 12 months vs. baseline (data not shown).
Discussion
In this study, which involved young, nonobese transsexuals, cross-sex hormone treatment influenced many of the components of the insulin resistance syndrome, with both regimens inducing favourable and less favourable changes with regard to cardiovascular risk. These results may be useful in interpreting sex differences (Tunstall-Pedoe et al., 1994; Jousilahti et al., 1999) and potential benefits and risks of administration of exogenous steroids [such as hormone-replacement therapy (HRT), contraception, androgen administration] in general (Barrett-Connor, 1995; Alexandersen et al., 1996; Herrington et al., 2000; Writing Group for the Women's Health Initiative Investigators, 2002).
Men have larger amounts of visceral (intra-abdominal) fat than premenopausal women, which is a stronger cardiovascular risk factor than weight or total body fat (Freedman et al., 1990; Seidell et al., 1991; Larsson et al., 1992; Lemieux et al., 1994) . This Table 2 Sex hormones, lipid profile, insulin sensitivity and body fat distribution parameters at baseline and after 2 and 12 months of testosterone administration in 17 female-to-male transsexuals n Baseline 2 months 12 months P-value 17β-oestradiol (pmol / l) 17 161 ± 55 134 ± 34 134 ± 35 ns Testosterone (nmol / l) 17 1·6 ± 0·6 41 ± 18 31 ± 11 < 0·001 SHBG (nmol / l) 17 58 ± 29 29 ± 12 25 ± 11 < 0·001 Total cholesterol (mmol / l) 17 predominance of fat in the visceral depot is associated with many disturbances of glucose and lipid metabolism. Yet, despite a gain in weight and a slight increase in visceral fat in both M-F and F-M groups, proportional changes were not related to those changes in insulin sensitivity, fasting insulin levels and blood pressure levels. Besides body fat distribution, exogenous sex steroids are likely to influence other components via direct effects on several tissues (liver, muscle and endothelium). Oestrogens are known to have some beneficial effects on the lipid profile in women, which we confirm in genetic males. The regimen of EE + CA raises plasma HDL-cholesterol and its subfractions HDL 2 -and HDL 3 -cholesterol -all being inverse predictors of atherosclerosis -which is consistent with findings in women using oral contraceptives (Crook & Godsland, 1998; Schaefer et al., 1983) or HRT (Bagatell et al., 1994) . The observed reduction in HDL-cholesterol and its subfractions upon testosterone administration is consistent with reports on the effects of exogenous androgens von Eckardstein et al., 1997; Singh et al., 2002) . We also report that oestrogens decrease and androgens increase HL activity, consistent with previous data Taggart et al., 1982; Tikkanen et al., 1982; Sorva et al., 1988; Applebaum-Bowden et al., 1989; Brinton, 1996) , which might explain the sex difference found in HL activity. As HL catabolizes phospholipids and triglycerides from HDL (as well as LDL) particles, changes in circulating HDL particles are in line with opposite changes in HL activity seen with the two hormone regimens (Kantor et al., 1985; Applebaum-Bowden et al., 1987) . Factors other than their lipolytic degradation may also determine HDL-cholesterol levels, such as their receptor-mediated removal or the hepatic synthesis of apo A-I, the main protein constituent of HDL (Brinton, 1996) .
The LDL particle is smaller in men vs. women (Krauss, 1994; Nikkila et al., 1996) , yet both regimens (oestrogen + antiandrogen administration to males, and androgen administration to females) induced an atherogenic lipoprotein phenotype of smaller, cholesterol-depleted, triglyceride-enriched LDL and increased triglyceride levels. In oestrogen-treated M-F transsexuals, cholesterol esters in LDL could have been exchanged by triglycerides from triglyceride-rich lipoproteins resulting in small, triglyceride-enriched LDL particles. In testosterone treated F-M transsexuals, the increased HL activity may have induced a cascade of lipid transfer and hydrolysis reactions (Zambon et al., 1993; Lagrost et al., 1994) . When interpreting calculated LDL protein values, the number of LDL particles seemed to have remained constant in either group.
Administration of EE + CA in M-F transsexuals reduced insulin sensitivity accompanied by elevated fasting insulin concentrations, the latter suggesting either a compensatory response or an increase in the metabolic clearance rate of insulin, or both. This confirms earlier observations by our group (Polderman et al., 1994) . By contrast, testosterone treatment in F-M transsexuals did not induce significant changes in fasting insulin levels or insulin sensitivity in the physiological range. Only a statistically significant reduction in the M-value was observed during infusion of supraphysiological levels of insulin, which is consistent with a study in healthy women, showing upon methyltestosterone administration that whole-body glucose uptake was not significantly affected during low-dose insulin infusion and decreased during high-dose insulin infusion (Diamond et al., 1998) . As only supraphysiological testosterone levels reduced glucose utilization, hyperandrogenism may not be the sole contributor to insulin resistance as found in hyperandrogenic women (e.g. polycystic ovary syndrome). Cross-sectional associations found in hyperandrogenic women are not indicative of a causal relationship, the opposite -hyperinsulinaemia causing hyperandrogenism -may also be true. Systolic and diastolic blood pressures were significantly raised by EE + CA administration in M-F transsexuals, which can have detrimental effects on blood vessels and cardiac function (MacMahon et al., 1990) . Several factors could mediate this increase, including an increase in body weight, body water retention by its influence on the central regulation of arginine vasopressin (Forsling et al., 1982; Stachenfeld et al., 1998) , hepatic synthesis of angiotensinogen and insulin resistance directly (DeFronzo & Ferrannini, 1991; Laws & Reaven, 1993) . Testosterone administration in F-M transsexuals did not affect blood pressure.
This study was limited by the small sample size and absence of a control group, yet we were able to show significant changes in many elements clustered in the insulin resistance syndrome. It should further be noted that the large dose of cyproterone acetate, a 17α-hydroxyprogesterone with potent antiandrogenic properties, could have contributed to the observed effects in M-F transsexuals. A better understanding of the benefits and potential risks of administering oestrogens is needed, as HRT is widely used by postmenopausal women (Manson & Martin, 2001) . Moreover, addition of androgen to oestrogen therapy is being considered in postmenopausal women as it has been shown to increase well-being and sexual functioning, and to have beneficial effects on bone and lipids (Dobs et al., 2002) . Results of this study may be also relevant in the understanding of cardiovascular effects of the prospective increasing use of (anabolic) androgens: by ageing males (Vermeulen, 2001) , by patients with chronic diseases (Basaria et al., 2001 ) and by reproductive males as an contraceptive agent (Handelsman et al., 1996) .
In conclusion, high-dose oestrogen + antiandrogens in M-F transsexuals have beneficial effects on HDL-cholesterol levels and the ratio between visceral and subcutaneous abdominal fat, but induces elevated triglyceride levels, smaller LDL particles, insulin resistance and hypertension. High-dose testosterone in F-M transsexuals has neutral effects on blood pressure and insulin sensitivity, but induces lower HDL-cholesterol levels, elevated triglyceride levels, smaller LDL-particles and an increased ratio between visceral and subcutaneous abdominal fat. The observed changes in metabolic risk factors do not support unequivocally that female sex steroids have beneficial effects on cardiovascular risk profile or that testosterone administration increases the risk for cardiovascular diseases.
